TCG Crossover Management, LLC — 13F Holdings & Portfolio
CIK 1839948 · latest 13F-HR filed 2026-08-14
TCG Crossover Management, LLC manages $4.16B in 13F-reported U.S. long-equity assets across 54 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (19.24%), TNGX (6.82%), CGON (6.27%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 12 new positions and exited 7; 27 existing positions rose in reported value and 11 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ABIVAX SA AMERICAN DEPOSITARY SHARES$78.9M +10.9%
- SPYRE THERAPEUTICS INC$72.9M +76.0%
- TANGO THERAPEUTICS INC$63.6M +28.9%
- IMMUNOVANT INC$61.0M +55.1%
- AVALO THERAPEUTICS INC$44.7M +405.8%
Top Trims
- ADC THERAPEUTICS SA-$30.5M -71.5%
- ENTRADA THERAPEUTICS INC-$21.1M -73.0%
- TYRA BIOSCIENCES INC-$20.7M -16.6%
- ARVINAS HOLDING CO LLC-$19.4M -76.8%
- ALX ONCOLOGY HOLDINGS INC-$14.4M -55.1%
New Positions
- ZAI LAB LTD-ADR$116.6M
- AURA BIOSCIENCES INC$67.7M
- FIRST TRACKS BIOTHERAPEUTICS$58.3M
- EDITAS MEDICINE INC$36.0M
- PHARVARIS BV$34.9M
Exited Positions
- CENTESSA PHARMACEUTICALS PLC$170.3M
- FULCRUM THERAPEUTICS INC$40.3M
- LIQUIDIA TECHNOLOGIES INC$15.2M
- UROGEN PHARMA LTD$7.3M
- STRUCTURE THERAPEUTICS INC$6.8M
TCG Crossover Management, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ABIVAX SA AMERICAN DEPOSITARY SHARES | ABVX | 00370M103 | $800.6M | 19.24% | 6,007,834 | SH |
| 2 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $283.9M | 6.82% | 9,081,201 | SH |
| 3 | CG ONCOLOGY INC | CGON | 156944100 | $260.8M | 6.27% | 3,670,206 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $187.9M | 4.52% | 4,854,436 | SH |
| 5 | IMMUNOVANT INC | IMVT | 45258J102 | $171.8M | 4.13% | 4,457,988 | SH |
| 6 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $168.7M | 4.06% | 1,900,582 | SH |
| 7 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $163.4M | 3.93% | 1,676,624 | SH |
| 8 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $124.3M | 2.99% | 1,062,049 | SH |
| 9 | ZAI LAB LTD-ADR | ZLAB | 98887Q104 | $116.6M | 2.80% | 6,137,627 | SH |
| 10 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $112.1M | 2.70% | 6,243,812 | SH |
| 11 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $111.9M | 2.69% | 4,622,151 | SH |
| 12 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $110.2M | 2.65% | 11,020,968 | SH |
| 13 | VOR BIOPHARMA INC | VOR | 929033207 | $104.4M | 2.51% | 5,673,078 | SH |
| 14 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $103.8M | 2.49% | 3,248,980 | SH |
| 15 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $102.5M | 2.46% | 4,615,144 | SH |
| 16 | DISC MEDICINE INC | IRON | 254604101 | $98.1M | 2.36% | 1,341,862 | SH |
| 17 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $80.0M | 1.92% | 4,273,356 | SH |
| 18 | SAVARA INC | SVRA | 805111101 | $76.2M | 1.83% | 12,362,205 | SH |
| 19 | AURA BIOSCIENCES INC | AURA | 05153U107 | $67.7M | 1.63% | 9,533,333 | SH |
| 20 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $63.8M | 1.53% | 340,899 | SH |
| 21 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $58.3M | 1.40% | 2,895,304 | SH |
| 22 | KODIAK SCIENCES INC | KOD | 50015M109 | $56.3M | 1.35% | 1,445,538 | SH |
| 23 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $55.8M | 1.34% | 3,017,120 | SH |
| 24 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $47.0M | 1.13% | 1,447,310 | SH |
| 25 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $43.4M | 1.04% | 17,754,430 | SH |
| 26 | TECTONIC THERAPEUTIC INC | TECX | 878972108 | $41.4M | 1.00% | 1,204,891 | SH |
| 27 | XENCOR INC | XNCR | 98401F105 | $39.5M | 0.95% | 2,452,138 | SH |
| 28 | SURROZEN INC | SRZN | 86889P208 | $38.2M | 0.92% | 1,473,101 | SH |
| 29 | EDITAS MEDICINE INC | EDIT | 28106W103 | $36.0M | 0.87% | 11,111,111 | SH |
| 30 | MBX BIOSCIENCES INC | MBX | 55287L101 | $35.9M | 0.86% | 650,000 | SH |
| 31 | PHARVARIS BV | PHVS | N69605108 | $34.9M | 0.84% | 1,008,229 | SH |
| 32 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $33.3M | 0.80% | 3,033,560 | SH |
| 33 | INFLARX N V | IFRX | N44821101 | $32.5M | 0.78% | 14,500,000 | SH |
| 34 | ALTIMMUNE INC | ALT | 02155H200 | $30.4M | 0.73% | 10,000,000 | SH |
| 35 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $27.5M | 0.66% | 1,789,617 | SH |
| 36 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $27.0M | 0.65% | 7,915,567 | SH |
| 37 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $26.7M | 0.64% | 2,053,233 | SH |
| 38 | BIOHAVEN LTD | BHVN | G1110E107 | $26.5M | 0.64% | 1,779,952 | SH |
| 39 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $22.5M | 0.54% | 696,560 | SH |
| 40 | ALECTOR INC | ALEC | 014442107 | $20.1M | 0.48% | 10,000,000 | SH |
| 41 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $19.6M | 0.47% | 920,000 | SH |
| 42 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $18.8M | 0.45% | 203,327 | SH |
| 43 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $16.2M | 0.39% | 1,647,752 | SH |
| 44 | ADC THERAPEUTICS SA | ADCT | H0036K147 | $12.2M | 0.29% | 11,390,175 | SH |
| 45 | ALX ONCOLOGY HOLDINGS INC | ALXO | 00166B105 | $11.7M | 0.28% | 5,655,487 | SH |
| 46 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $7.8M | 0.19% | 1,060,230 | SH |
| 47 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $7.4M | 0.18% | 406,786 | SH |
| 48 | ARVINAS HOLDING CO LLC | ARVN | 04335A105 | $5.9M | 0.14% | 707,098 | SH |
| 49 | KORRO BIO INC | KRRO | 500946108 | $5.5M | 0.13% | 416,301 | SH |
| 50 | RESEARCH ALLIANCE CORP CL A | RACC | G75226103 | $5.3M | 0.13% | 500,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $4.16B | 54 | 0001214659-26-010290 |
| 2026-03-31 | 2026-05-15 | $3.50B | 49 | 0001214659-26-006367 |
| 2025-12-31 | 2026-02-17 | $3.02B | 43 | 0001214659-26-001871 |
| 2025-09-30 | 2025-11-17 | $2.03B | 40 | 0001214659-25-016751 |
PALO ALTO, CA 94301